Earnings call
Jubilant Ingrevia Q3 FY25 earnings call: Jubilant Ingrevia’s Pinnacle 345 targets 3x growth and 4 times EBITDA in the next 5 years
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
Pinnacle 345 targets 3x growth and 4 times EBITDA in the next 5 years. The company has commissioned its cosmetics grade and food grade B3 plant and hopes to catch up with the number 1 position once the plant fills up its capacity. Specialty portfolio grew 20% in the first 9 months, and its profitability improved significantly. The company has maintained 75%+ market share in the domestic market for acetic anhydride. The company has around half a dozen products in its Diketene portfolio and hopes to add another half a dozen in the next 12 months.
The numbers management gave
Results
- Specialty portfolio grew 20% in the first 9 months, and its profitability improved significantly.
Show source
The Specialty portfolio has grown 20% in the first 9 months, the profitability has improved significantly, Nutrition similarly has grown 8%, part of it grew more because of the price.
- Nutrition business grew 8% in the first 9 months, partly because of price, and its volume grew probably 15%.
Show source
In terms of volume, we have grown probably 15%.
- Cost imperatives have taken out almost Rs. 100cr+ from its cost structure.
Show source
But at least, if I look at our growth journey over the last few years we have seen volume growth, profitability has improved, as I said in the beginning, based on the 2 key drivers - no 1 is the portfolio shift we are doing and no. 2 is the cost imperatives which has helped us take out almost Rs. 100cr+ from our cost structure.
- Europe business grew almost by 30% in the first nine months of this year.
Show source
Europe also grew almost by 30% in the first nine months of this year, and we are hoping with the confidence that the European and American customers have shown us, we'll continue to grow this.
- The company grew Pyridine and Picoline volumes by 150% and beta-picoline merchant sales, excluding captive sales, by 10%; merchant sales have more than 25% market share.
Show source
So, with this, I will talk about our Pyridine and Picoline, which is our legacy business which if you can see, we have been able to grow our volumes by 150%, we have been able to grow our beta-picoline, other than our captive, 10%, so, these are all merchant sales where we have more than 25% market share.
- The company has grown its ethyl acetate business almost 30%.
Show source
Other key products, you know, what we have in this time, apart from focusing on acetic anhydride, we have grown almost 30% of our ethyl acetate business.
Show 8 more statements
Results
- The company has increased its acetaldehyde business almost 180% and has started exporting acetaldehyde.
Show source
Propionic-Anhydride, we have increased our business in this, acetaldehyde, you know, almost 180% we have increased and this product we have not only increased in India, we have also started exporting this product.
- The company has achieved a 17% improvement in energy.
Show source
Energy, as I said, already explained to you, 17% improvement we see there.
- The company expects 50% of its planned 100cr savings to come from energy next year.
Show source
Vijay Srivastava: So, this 100cr savings we are expecting to come from few critical assets, energy will go on to be a driving factor where 50% of the savings is expected to come next year.
- The company expects savings from norm improvement and effluent treatment, as well as energy.
Show source
After that, norm improvement is the second area we are working on, third is the effluent treatment.
Money and capital
- The company invested some Rs. 2,000crs in its business over the last 4 years or so.
Show source
So, it was critical to bring lot more focus, lot more investments in those businesses and that’s exactly what has been happening over the last 4 years or so when we invested in the business of some Rs. 2,000crs, created new R&D centres and hired and grew the team over the last few years.
- The company will invest only in projects with a return of at least 20%.
Show source
Nothing less than 20% return will be invested in.
- The company will fund most of its growth capex through EBITDA generated as profitability increases and cash conversion touches 100%.
Show source
So, most of it will be funded through our internal accruals as our profitability increases and our cash conversion touches 100, the first port of call will be the growth capexes, and while the timing plays a factor here, most of it, the lion’s share will be through the EBITDA that we generate.
- The company has invested almost Rs. 1700cr over the last 3 years, while its loan is still only at Rs. 750cr.
Show source
We have invested almost Rs. 1700cr and our loan is still only at Rs. 750cr, so we have, whatever internal accruals we have generated through the EBITDA and through the efficiencies, we have reinvested and that’s the plan.
What it expects ahead
What management expects
- Pinnacle 345 targets 3x growth and 4 times EBITDA in the next 5 years.
Show source
As Deepak has shared before, his ‘Pinnacle345’ journey, which aims for 3 times revenue growth and 4 times EBITDA growth in the next 5 years.
- The company aspires to be in the top 3 in Diketene, in India and globally, and is developing a product portfolio with products in R&D phase to help achieve this in coming years.
Show source
Some of the new aspects of our business, the growth factors we will talk about in the next half an hour, you will see the starting aspirations, Diketene being the prime example, our aspiration is to be in the top 3, in not just in India, but globally and that’s what all the investments are about, all the portfolio we are developing, the products which are in R&D phase, will help us get there in coming years.
- The company expects exports to be almost 70% of its business in the coming years.
Show source
But, going forward, we expect exports to be almost 70% of our business in the coming years.
- R&D spend is probably less than 1% at a company level and, even excluding acetyl, is on the lower side; it expects to double its R&D spend in the coming years to support innovation for growth.
Show source
At a company level, we are probably less than 1% but even if I take acetyl out, which skews it, still we are on the lower side and we expect to double it up in the coming years because that is the kind of innovation that is needed to fuel our growth aspirations.
- Trailing 12-month topline in 2024 was about Rs. 4,200cr, and the company hopes to reach Rs. 12,000cr.
Show source
So, almost on every aspect, we are working on and the hardware part I already talked about and what it means in terms of numbers is that, if you take 2024, the trailing 12 months, we are about Rs. 4,200cr in the topline, we hope to get to Rs. 12,000cr.
- The company expects to bridge its Rs. 2,000cr gap through inorganic opportunities or by finding new platforms along the way.
Show source
We feel that we will be able to figure out how to bridge that gap through inorganic opportunities or by finding new platforms along the way.
Show 65 more statements
What management expects
- The company has a bottom-up plan for almost Rs. 10,000cr in topline, with a Rs. 2,000cr gap to its vision. Based on its current products, platforms and visibility, Jubilant Ingrevia is confident it can deliver organically at least Rs. 10,000cr through its bottom-up plan.
Show source
In all honesty, we have a bottom up plan which takes us to almost Rs. 10,000cr, we have a gap of Rs. 2,000cr but still that vision.
- The company will keep investing in the business; its ROCE can be skewed by whip capex, but every investment has a business case banking on 20%+ ROCE, and the majority of its future portfolio will have 20%+ ROCE.
Show source
But on the back of all these efforts, the portfolio shift towards high margin segments and the cost improvement efforts, we have embarked to get to Rs. 2,000cr EBITDA and ROCE, I mean, it has improved over the last 4 quarters from 9-10% to almost 12%, we have a path to take it to 17- 20%, obviously we’ll keep investing in the business, so sometimes the ROCE Page 9 of 36 number gets skewed by what we call the whip capex but adjust it so that every investment we are making in the company has a business case which is banking on a 20%+ ROCE and hence, majority of the future portfolio, most of it, I mean, all of it will be 20%+ ROCE.
- The company expects its semiconductor chemicals portfolio to continue growing in the coming 3-5-7 years, supported by customer traction and partnerships.
Show source
Semiconductor Chemicals customers will take few more years before they can start outsourcing in a big way, but we feel we are one of the early movers here and on the back of all the traction, partnership we are getting with our customers, we feel that portfolio will continue to grow in the coming 3-5-7 years.
- The company is running most Chemical Intermediates capacity at 70% utilization, even in tough times, and believes it can raise utilization to at least 85-90% in coming years by pushing more volumes.
Show source
We believe that with the leadership positions and the cost structures we have and the global presence we have in these products, we should be able to push more volumes in the coming years and take those utilizations up to at least 85-90% in the coming years.
- The company expects Specialty and Nutrition to become almost 75-80% of its portfolio in the next 4 or 5 years, with Specialty taking almost 60% share, largely driven by investments in CDMO and Fine Chemicals.
Show source
These two businesses will become almost 75-80% of our portfolio in the next 4 or 5 years with Specialty taking almost 60% share and largely growing on the back of all the investments we are making in CDMO and Fine Chemicals portfolio.
- The company expects exports to become almost 60%, 65% of its portfolio.
Show source
Like I said, exports will become almost 60%, 65% of our portfolio and you can see how fast America is already growing.
- The company expects America to become almost 20-25% of its portfolio in coming years.
Show source
We expect America to become almost 20-25% of our portfolio in coming years.
- The company expects the Agro share of its portfolio to remain 25-30%.
Show source
As I said in the beginning, it's anyway even stable times almost 25% of our portfolio so it will remain 25-30%.
- The company estimates that its addressable TAM or SAM will grow at least 15% in any or all of the domains where it is present.
Show source
The TAM or SAM, serviceable market for us, will be growing at least 15% in any of the domains or all the domains where we are present.
- The U.S. accounted for 4% to 5% of Jubilant Ingrevia's portfolio previously and almost 9% in the last quarter; the company expects it to reach 15% plus by FY27 and wants it to reach 20%, 25% in the next five years.
Show source
Today, last quarter results, almost 9%, and we are on track to hopefully, by FY27 itself, it should become 15% plus, and obviously in the next five years, we want to make it 20%, 25%.
- The company has 6 Diketene products and will launch 4 this year.
Show source
We have 6 products, 4 we will be launching this year.
- The company believes it can grow its existing Fine Chemicals business almost 2 times in the next 4-5 years, supported by its experience in ketene chemistry since 1980 and Diketene for the last few years.
Show source
So, Diketene as a chemistry, we have been doing acetic anhydride which is primary Ketene and Diketene has been a natural extension, so based on these extensions, we believe that acetic anhydride, we have been handling ketene chemistry for the last, since 1980, for 40 years+, diketene for last few years but we can play this game really, for a really long time and we are pretty confident that we will be able to grow this existing business almost 2 times in the next 4-5 years.
- The company is hoping for 7x growth by FY30, with multiyear contracts with Agro innovators covering existing and new molecules.
Show source
So, all put together, by FY30, it would be something like 7x growth happening and what we are hoping aggressively and so we are hoping with multiyear contracts happening with the Agro innovators which is not only just for existing molecules, we are getting into new molecules.
- Nutrition and Health Solutions business aims to triple revenue by FY30 and almost double the bottom line, increasing its current 12% EBITDA margin to 18-20%.
Show source
So, in terms of the pinnacle vision for the business, nutrition and health solutions business, so, our vision is to triple the revenue by FY30 and almost double the bottom line, so almost current 12% EBITDA margin, we want to take it to 18-20% and how we will do this, the growth drivers that you can see on the right hand side of the slide.
- Food, cosmetics and speciality pre-mixes account for 33% of Jubilant Ingrevia's Nutrition and Health Solutions segment revenue currently, will increase to 36% this year, and will reach 67% by FY30.
Show source
So, currently if you see, 33% of our revenue in nutrition and health solutions segment comes from food, cosmetics and speciality pre-mixes.
- The company has commissioned niacinamide for food grand and cosmetic grade and is ramping up its volumes, with the aim of becoming number 1 in niacinamide globally.
Show source
Then niacinamide which has already been commissioned for food grand and cosmetic grade, we are ramping up the volumes for that and very soon we will take up the leader board and number 1 position in niacinamide globally and we are adding more pre-mixes in the feed additives segment.
- Chemical intermediates business is proposing to increase its topline by 1.5 times from around Rs. 1700cr, with around 8% of EBITDA.
Show source
As such, we are looking at an increase by 1.5 times in the topline, currently we are somewhere around Rs. 1700cr of the topline with around 8% of EBITDA.
- Chemical intermediates division is targeting at least Rs. 2500cr in topline and 10-12% EBITDA by FY30.
Show source
So, what we are looking at, by FY30, we should be atleast Rs. 2500cr for chemical intermediates division with 10-12% EBITDA, which is a normal, standard % in our kind of business.
- The company expects margins in its chemical intermediates division to increase and reach 10-12% EBITDA levels as it moves along.
Show source
And, of course, as we move along, the margins will increase and then we could again see the 10-12% EBITDA levels.
- Aspiration is to obtain lighthouse status for at least one more plant within the next 2 years.
Show source
We got lighthouse for one of our facilities, our aspiration is to get it for atleast one more plant within next 2 years and we are working towards that by introducing all these interventions across all the other plants as well.
- The company has a line of sight to achieve additional Rs. 100cr saving each year moving forward.
Show source
We have a line of sight to get additional Rs. 100cr saving each year moving forward.
- ROCE increased from sub 8% last year to 12% in the last quarter reported, and the company intends to take it to 17-20% in the coming years.
Show source
One key metric that we keep tracking is our ROCE, from sub 8% last year it has gone up significantly to 12% in this last quarter that we reported, and we intend to take it to 17-20% in the coming years.
- Exports are expected to increase from a current 45-50% to 60%+ in the future, while its spread of chemicals will be more than 60%.
Show source
As Deepak shared, our exports will increase from a current 45-50% to 60%+ in the future and our spread of chemicals will be more than 60% so that’s the one key big driver.
- Savings program is expected to deliver Rs. 100cr+ per annum through systematic savings that permanently take cost out of the business.
Show source
Second, as Vijay mentioned, the savings program that we have unleashed in the organization which is going to consistently deliver Rs. 100cr+ per annum will increase the return substantially.
- Cash conversion to EBITDA increased from sub-90% last year to 100%, and the company intends to maintain it for the coming quarters by optimizing working capital, increasing credit days, managing inventory and releasing cash from tapped assets.
Show source
From a sub-90% last year, we are sequentially going to, are delivering 100% cash conversion to EBITDA and we intend to keep it this way for the coming quarters.
- The company will try to reduce net debt to EBITDA from 1.5 to a range of 1.2-1.3 by improving ROCE and profitability ahead of investment plans.
Show source
The second one is really how do we manage our net debt, so we will try to reduce it from 1.5 and bring it down to the range of 1.2-1.3 by improving our ROCE and profitability ahead of investment plans.
- The company intends to reach ROCE of 17-20% sooner than later.
Show source
So, these 3 drivers will improve the ROCE sequentially, and we intend to reach it sooner than later, 17-20%.
- The company expects to deliver 100% cash conversion to EBITDA in the coming quarters.
Show source
From a sub-90% last year, we are sequentially going to, are delivering 100% cash conversion to EBITDA and we intend to keep it this way for the coming quarters.
- The company expects a net debt to EBITDA ratio of around 1-1.3 as a result of Pinnacle 345.
Show source
ROCE, as I mentioned, from 8%, we are already touching 12% in the last quarter through portfolio mix and better cost savings and more discipline, and the net debt to EBITDA ratios to be in a controlled way in around 1-1.3, these are the 4 key matrices that we will there as a result of Pinnacle 345.
- The company expects topline of Rs. 10-12,000cr by financial year 2030 and EBITDA in the range of Rs. 2,000cr by 2030, four times the level from where it started.
Show source
So, if I have to summarize, what this entire transformation will mean like, we’ll be touching Rs. 10-12,000cr of topline by financial year 2030. and if I have to see if we are on track of it, 4 times on EBITDA from where we started, so, in the range of Rs. 2,000cr by 2030. and if you see this year’s results for the first 3 quarters there’s a big improvement we have done from where we started a year back.
- The company hopes to reach Rs. 10-12000 cr in the next 5 years with higher margins closing almost 17-18% at least, on the back of the growth drivers discussed.
Show source
Number 2, the growth is rapid and we are hoping to touch the Rs. 10-12000 cr in the next 5 years with higher margins closing almost 17-18% atleast, if not more on the back of all the growth drivers we discussed today.
- Some of Jubilant Ingrevia's new growth platforms may deliver meaningfully large revenues in the next 4-5 years, while some may take longer.
Show source
Some of them will give meaningfully large revenues in the next 4-5 years, some of them may take longer, but the idea is to create this platform in not just the next 4-5 years but also for the growth that we foresee even subsequent to that.
- The company expects new capex to generate a minimum 20-25% ROCE; in specialty chemicals, asset turnover is typically in the range of 1.2-1.5 at best, including for a CDMO contract.
Show source
Any new capex that we will do should give me a minimum of a 20-25% ROCE and typically in a specialty chemical, be it a CDMO contract the ratio of the asset turnover should be in the range of 1.2- 1.5 at the best.
- The company does not expect prices in most segments to recover meaningfully anytime soon because of overcapacity in China; it expects at least 2-3 years before prices show any recovery.
Show source
So, our say is that it will take atleast 2-3 years for prices to show any kind of recovery in all likelihood to, we have come to a new normal.
- The company is not expecting explosive growth in its acetyl business over the next 5 years and expects 1.5 times sales based largely on volume recovery and some price recovery.
Show source
As Himanshu showed in acetyl business, we are not expecting an exploded growth in the next 5 years, 1.5 times sales based on, largely volume recovery but a little bit price recovery as well.
- The company expects most of its major revenue in the next 5 years to come from non-pyridine products.
Show source
Ambrish Dixit: I think we can share that in the next 5 years of our major revenue would be coming from non-pyridine.
- The company says 50%+ of its revenue would be non-pyridine.
Show source
50%+ revenue would be non-pyridine.
- The company is hopeful that peak revenues from investments made in the last 3 years will be reached in FY27; because of market recovery and slowness in the last 2 years, the peak ideally would have been reached in FY26.
Show source
I think we have invested heavily in the last 3 years, we are hopeful that the peak revenues on the back of those investments will hit in FY27 and a part of it in the market recovery and the slowness in the last 2 years otherwise, ideally, we should have hit the peak in FY26 but nevertheless, all the investments we have made so far, we will hit the peak revenue on the back of that by FY27 but for hitting the numbers we have for FY30, we will need to continue to invest in the business and the quantum could be even bigger than what we have invested in the past, to get that incremental growth in revenue that we are aspiring to get.
- The company expects its CDMO business to be the biggest driver of its growth and profitability in the coming years.
Show source
We have gotten our CDMO business off the ground over the last 4 years and you will see later on in the presentation, that is going to be the biggest driver of our growth and profitability in the coming years.
- Most of Jubilant Ingrevia's growth will come from its Specialty and Nutrition portfolio, improving its profile.
Show source
The bulk of the growth, I will show on next page, will come from Specialty and Nutrition part of the portfolio which eventually means our profile will improve significantly.
- The company recently decided to scale up its cosmetics portfolio by leveraging its products, supply and customer strengths, and plans to capitalize on existing products and grow the portfolio.
Show source
We feel that it is the right time to leverage all those strengths, be it on the products side, or supply side or customer side to scale up this portfolio and this is something we have only recently decided and of course, we have a set of products existing for several years, but we are going to capitalize on them and grow their portfolio.
- The company plans to enter premixes and some formulations for its Human Nutrition portfolio and hopes to grow them in coming years.
Show source
So, these are the products for the Human Nutrition portfolio but on the back of it, we have plans to get in the premixes and some of the formulations which we are just starting the journey on and will hopefully grow in coming years.
- Most incremental growth in Jubilant Ingrevia's Chemical Intermediates portfolio will come from existing capacities.
Show source
So, most of the incremental growth in this portfolio will come from the back of existing capacities.
- The company expects the Consumer share of its portfolio to become relatively bigger, driven by cosmetics and hair care.
Show source
So pharma, agro, and nutrition will thrive and consumer will become relatively bigger on the back of what I said on the cosmetics and hair care space.
- The company believes the markets for paracetamol and acetate have bottomed out and that de-stocking is done; it expects volumes to start returning in the next couple of quarters and prices to move upwards gradually over a couple more quarters.
Show source
The de-stocking is done there, and hopefully in the next couple of quarters, the volumes will start to come back there as well.
- The company is hopeful that Chemical Intermediates will start to come back, while noting that the business is a relatively commodity product subject to commodity cycles.
Show source
So we are hopeful that Chemical Intermediates will start to come back, but that's a relatively commodity product, and we'll have to live with those commodity cycles.
- The company hopes to establish Japan separately from the rest of the world within a couple of years, as it works to open up that market.
Show source
So, we are hoping in a, if not in a few quarters, definitely in a couple of years, from the rest of the world, we'll be able to carve out Japan separately with all the push and hard work we are doing in that market to open it up.
- The company believes its relationships with large global players will enable it to diversify its pyridine derivatives sales in the US and Middle East.
Show source
I think, Deepak also talked about oil fields, so we also sell certain pyridine derivatives in oil fields, and we believe that the kind of relation we have with the large players across the globe, US, Middle East, etc., we would be further diversifying launch in these 2 regions.
- PNP business will continue to have very high captive demand from its FC and CDMO businesses, helping it optimize margins.
Show source
And, last but not the least, PNP will continue to have very high captive demand from our business in FC and CDMO which will allow us to optimize on the other margins.
- The company says innovators and new molecules in the pipeline will come to it because it is the only non-Chinese player able to play large.
Show source
We are also further exploring talking to innovators or any new molecule which is in the pipeline will definitely come to us due to our unique position of being non, the only non-Chinese player who can play large.
- The company expects its CDMO business to have some good revenues starting from next year onwards, although chemistry capabilities and purification pose challenges.
Show source
We believe, you know, we thought we helped the revenues come a little early but definitely there are more challenges in terms of chemistry capabilities or purification etc. But we believe that we should be able to have some good revenues very soon, starting from next year onwards.
- The company plans to maintain its market share in India, grow its market share in Europe and enter South-East Asia, US and Turkey to grow its chemical intermediates division.
Show source
The critical role is that we will maintain our market share and we will grow our market share, we will maintain our market share in a market like in India, and we will grow our market share in a market like Europe, and we will also enter into new markets which we have either not touch based or not focused on in the past, where South-East Asia being a market, US being a market, Turkey being a market for that matter, in all those areas.
- The company is following up with customers on potential opportunities to try to convert them into commercial revenues; some opportunities remain ideas at this stage and may not materialize.
Show source
Now, of course, not all of those will materialize because some of them are just ideas at this stage but what it does is a very clear sense of potential opportunities and areas where our customers are focusing on and we are now in a focused way speaking to those customers, following up on our discussion to see if we can convert any of the opportunities into real commercial revenues for ourselves.
- The company expects savings from effluent treatment projects this year and next year.
Show source
Now similar project we have built for other product as well and I think this year and next year we will continue to get savings from effluent treatment setup.
- The company will invest in new growth platforms in semiconductors, cosmetics, human nutrition and, to some extent, oil field.
Show source
Creating new growth platforms, semiconductors, cosmetics, human nutrition and to some extent, oil field also which Ambrish talked about, these are the new growth vectors which we can already see and smell the opportunities in these areas, we will invest.
- The company expects the market to recover in the near term, with volumes returning in its core segments and the volume recovery not being delayed further.
Show source
And atleast the indicators suggest that assumption is a valid one and the volume recovery will not get delayed any further.
- Base-case scenario keeps prices flat in most segments, with marginal uptakes in some segments.
Show source
But the base case scenario we are building is keeping the prices for most segments where there are marginal uptakes in some segments.
- The company expects acetic acid prices to recover as volumes return, which could lift prices of acetic anhydride, its core product; this is an assumption.
Show source
There, we are hoping that as volumes come back, the acetic acid, which is a driver for acetic anhydride, which is our core product, the prices should come back.
- The company expects its numbers to double while India's contribution comes down as a whole, including in nutrition and other businesses.
Show source
So, overall, the numbers will double, India will come down as a whole, even nutrition and any other business.
- The company says customers seeking pyridine beyond China have no option but to come to it, and that most of its growth will come from non-pyridine areas.
Show source
But bulk of our growth will come from non-pyridine areas.
- The company will need to continue investing in the business to reach its FY30 numbers, and the investment quantum could be even bigger than it has invested in the past to achieve the incremental revenue growth it aspires to.
Show source
I think we have invested heavily in the last 3 years, we are hopeful that the peak revenues on the back of those investments will hit in FY27 and a part of it in the market recovery and the slowness in the last 2 years otherwise, ideally, we should have hit the peak in FY26 but nevertheless, all the investments we have made so far, we will hit the peak revenue on the back of that by FY27 but for hitting the numbers we have for FY30, we will need to continue to invest in the business and the quantum could be even bigger than what we have invested in the past, to get that incremental growth in revenue that we are aspiring to get.
- The company has a bottom-up plan for almost Rs. 10,000cr in topline, with a Rs. 2,000cr gap to its vision. Replaced by a later filing.
- The company wants to become the leader provider of innovative solutions in its core chemistry. Replaced by a later filing.
Show source
We want to be the leader provider of innovative solutions in our core chemistry.
- The company says Specialty will increase as part of its transformation. Replaced by a later filing.
Show source
This will require some fundamental shifts and already a lot has been talked about, so I won’t deliver the points on this page but this is the true transformation in making and we have taken the first few steps, as we said in the beginning, given our confidence that we are on the right track, we’re on the right journey but the Specialty will increase, the customer centricity of course, some of you speak to our customers also and we feel very happy when we hear the feedback of the customers through some of you.
Orders
- Of the two big agro molecules Jubilant Ingrevia recently won and announced, one is pyridine and one is non-pyridine; the company hopes that ratio will be maintained.
Show source
In agro, the 2 big molecules we won are, recently which we announced, one is pyridine, and one is non-pyridine, so we hope that ratio will maintain.
What it is building and selling
Projects and capacity
- The company has commissioned its cosmetics grade and food grade B3 plant and hopes to catch up with the number 1 position once the plant fills up its capacity.
Show source
The second pillar of our business is the Nutrition business, which is where we have Vitamin B3, we are globally number 2 and we have just commissioned our cosmetics grade and food grade B3 plant and once it fills up its capacity, we are hoping that we will catch up with number 1 position very soon.
- The company has no plans to invest more to increase capacity in its Chemical Intermediates portfolio and has initiated at least 10 cost-optimization initiatives for acetic anhydride, ethyl acetate, acetaldehyde and other products.
Show source
We don’t have any plans to invest more to increase the capacity in the Chemical Intermediates portfolio which just started and obviously we are working continuously on the cost structure and we have already turned at least 10 different initiatives to optimize the cost structure of our acetic anhydride, ethyl acetate, acetaldehyde and other products portfolio and we will continue to work on that.
- Diketene plants are already being utilized at 70%; it launched 2 new plants within the last 1 year and is scaling up further.
Show source
We are actually you know, 70% of our plants already being utilized, we have launched 2 new plants within last 1 year, we are scaling up further.
- Pharma business has 9 molecules under development.
Show source
Here, as I already shared, we have more accelerated our efforts to hire more resources, we have 9 molecules under development, we have already known some certain innovators for a very good long time.
- The company created 6 new plants in 1-1.5 years and plans to create at least 2-3 more in the coming 12 months.
Show source
We created 6 new plants in 1-1.5 years, and we have plans to create at least 2-3 more in the coming 12 months.
- The company has 7 multi-purpose plants for pyridine derivatives, with certain streams dedicated to certain molecules where volumes are large; some products run 24x7x365 days and others on a campaign basis.
Show source
Ambrish Dixit: So, I think, you know, on the pyridine derivatives side, we have 7 plants which are multi-purpose plants, there are certain streams which are dedicated for certain molecules where volumes are large but these are all multi-purpose plants, then you know, certain products are 24x7x365 days, certain products are on campaign basis, so, it’s a mix of the lot.
Show 54 more statements
Projects and capacity
- The company has 7 multi-purpose plants in Gajraula and is building the 8th one.
Show source
We have 7 multi-purpose plants in Gajraula and building the 8th one.
- The company is planning to invest further in a new GMP facility; it already has 3 ones and is planning to put up more on the operational areas side to produce volumes of intermediates, primarily on the pharma side.
Show source
There is the reason why we are also planning to invest further into a new GMP facility, we have 3 ones already but we are planning to put up more on the operational areas side so that we can produce the volumes of these intermediates, primarily on the pharma side are and agro anyway we have been talking big, so those numbers will continue to grow.
- Construction for a Jubilant Ingrevia contract signed in October is in full swing and is expected to be ready by October, November this year, with revenue benefits starting Q4 of FY26.
Show source
The construction is in full swing and will be ready hopefully by October, November this year so that we can start getting benefit of revenues coming from that project starting Q4 of FY26.
- The company is modifying one of its multipurpose plants, with revenue expected to start by the middle of this calendar year.
Show source
So that is also ongoing and that will start kicking in and giving revenues as I announced I think couple of quarters back in the investor call by middle of this calendar year.
- The company plans to multipurpose its various products for Diketene.
Show source
We are also planning to multipurpose our various products for Diketene.
- The company has identified certain molecules for its Semicon business that are under discussion.
Show source
So, what we have done, we have gone to the US, we have gone to Japan and Taiwan, we have, to understand what kind of synthetic chemistry has been asked for, and here we have been further able to identify certain molecules which are under discussion.
- The company is working to launch a Pyridine and Picoline molecule for semiconductor and electronics applications, with reasonable volume expected.
Show source
Where we are also in the process of working out and launching this molecule where there should be reasonable volume coming in.
- The company is working on specific plants and labs for its semiconductor and electronics molecule, and approval timing will be shared by Deepak.
Show source
And then, this requires capex, this requires specific plants, specific labs, which we are also working on and so Deepak will the one sharing the news in terms of when we are going to get it approved.
- The company has commenced production at its new niacinamide cosmetic-grade plant and plans to ramp up niacinamide cosmetic-grade and food-grade production.
Show source
So, the first is niacinamide cosmetic grade, so we have already commenced production for the newly commenced plant for the niacinamide cosmetic grade that we will double down and ramp up the niacinamide cosmetic grade and food grade from there.
- The company is working on capex for a green filed GMP plant for choline chloride and choline bitartrate.
Show source
We are also to go ahead with the capex, we are working on green filed GMP plant for choline chloride and choline bitartrate, and the third one is speciality formulations, now speciality formulations, these go into animal feed, these are like vitamins, minerals pre-mixes, emulsifiers, herbal formulations which go into feed which has more higher margin and more stickiness with the customer and which has more traction in India and the neighbouring markets.
- The company is planning capex for a Green Field GMP manufacturing facility for choline chloride and choline bitartrate.
Show source
Then, we are pushing on CC CBT, which is the choline chloride and choline bitartrate, vitamin B4, and as I have said, we are planning to take a capex for that for Green Field GMP manufacturing facility for that.
- Capex plan for the next few years will be predominantly investments in specialty chemicals, including CDMO multi-purpose plants or a new GMP facility as and when the business comes for CDMOs.
Show source
Varun Gupta: So, the capex plan for the next few years will be predominantly investments in specialty chemicals as we have outlined, which will include investments in the CDMO in the multi-purpose plants or into a new GMP facility as and when the business will come for CDMOs.
Demand and pricing
- The company has maintained 75%+ market share in the domestic market for acetic anhydride.
Show source
We are world number 1 or number 2 in merchant market capacity, depending on which year you talk about, and we are continuously expanding share in international markets, like Europe, and we have maintained our 75%+ market share in the domestic market.
- After an international competitor closed its US operations, Jubilant Ingrevia captured 70% of that competitor's Pyridine volumes within six months.
Show source
One thing I did not mention is in Pyridine, when one of our international competitors closed down in the US, within six months we grabbed 70% of their volumes.
- After US company Vertilabs closed around end of 22-23, Jubilant Ingrevia captured 75% of its accounts.
Show source
We have, you know, Vertilabs, which was a US company that got closed around end of 22-23 and then we have been able to capitalize all those accounts, so rather than the Chinese getting intrigued by the margins, we have been able to sell, we have been able to capture 75% of those accounts which has also helped us to sell more volumes in markets.
- The company has around 74% market share in India for acetic anhydride and has maintained its market share in Europe amid challenges associated with the Ukraine war.
Show source
So, we are around 74% market share in India despite all the challenges and we are looking at Europe market at, you know, in Europe, you have already seen, because of the Ukraine war, it has been a challenging involvement overall, but there also we have been able to maintain our market share.
- The company has maintained its market share and increased its market share in India for acetic anhydride despite a depressed market.
Show source
But I can assure you that we have not only maintained our market share, we have increased our market share even in this depressed market.
- The company has significantly grown its acetic anhydride market share in the RoW market, excluding India and Europe.
Show source
In fact, we have also grown our market share, if I leave India and Europe outside, we have significantly grown our share in the RoW market.
Segments
- The company has around half a dozen products in its Diketene portfolio and hopes to add another half a dozen in the next 12 months.
Show source
We have added Diketene as a new platform and we already have around half a dozen products in our portfolio, and we are hoping to add another half a dozen in the next 12 months.
- Specialty business is about 42% of its portfolio.
Show source
We have the Specialty business, which is the biggest part of our business, about 42% of our portfolio.
- Specialty chemicals business is almost 43% of its business.
Show source
This is the current profile of the business, business wise I have already talked about the specialty chemicals almost 43%, the biggest business, acetyl still remains big and is fundamental to our business, it’s a core business.
- Agro business share varies between 20 to 25%; it has come down to 20% because the market has not been very good over the last couple of years, and touches almost 25% in stable times.
Show source
It also seeps into other businesses, Nutrition almost 20%.
- Nutrition business is growing almost 22%.
Show source
Pharma is almost one-third of our business, Nutrition is growing very fast, almost 22%.
- The company created a reasonably scaled Diketene derivatives business within the last two years, and it is growing at almost 50% every year.
Show source
We have created a reasonably scaled business within the last two years, which is growing at almost 50% every year.
- Pharma CDMO pipeline doubled in size within the last 6-9 months and has almost 12 molecules confirmed by customers.
Show source
Within last 6- 9 months we have doubled our funnel size and there are almost 12 molecules which are confirmed by the customers.
- Within a year of focusing on semiconductor chemicals, Jubilant Ingrevia built a pipeline of almost 8-10 molecules where customers have confirmed at least kg volumes, and it has started supplying samples to almost 3-4 customers.
Show source
We started focusing on it and within a year we have been able to build a pipeline of Page 11 of 36 almost 8-10 molecules where customers have already confirmed at least kg volumes and we have already started supplying samples to almost 3-4 of them.
- The company has 36+ PNP derivative products for which it is number 1 in the globe, with market shares typically from 50%+ to 75% and an average of 55%; it wrapped up 5 new products in the last 1 year.
Show source
Here, we have 36+ products where we are the number 1 in the globe, we have typically from 50%+ to 75% market share average to 55%, we have 5 new products we wrapped up in last 1 year.
- The company is globally number 2 in niacinamide and a domestic leader in choline chloride in animal nutrition, and has more than 18 branded formulations for feed additives.
Show source
So, in animal nutrition we are globally number 2 in niacinamide which is vitamin B3, and we are domestic leaders in choline chloride, which is vitamin B4.
- Around 74% of Jubilant Ingrevia's revenue comes from export markets, and 69% of its Nutrition and Health Solutions business comes from animal nutrition; the business has around 400+ customers globally.
Show source
So, our customers is very robust and so we have around 400+ customers globally who have been associated with us for a long time and in terms of split between animal and human nutrition, so, 69% of our business comes from animal nutrition and balance comes from human nutrition.
- The company has a portfolio of 130+ products.
Show source
So, for these 30+ customers, we did a bottom-up mapping of all opportunities across our portfolio of 130+ products that we have today but also studied what their priorities are.
- Nutritional portfolio mix is almost flipping from 67-33 to 33-67.
Show source
Number 3 , increased focus towards high value and specialty segments in our overall specialty portfolio but also in our nutritional portfolio as Ashish showed the mix almost flipping from 67-33 to 33-67.
- Pharma portfolio business is 70% non-pyridine today.
Show source
Even today, 70% of my business is non-pyridine.
- About 65% of Jubilant Ingrevia’s CDMO molecules are in the in-phase stage and the remaining 35% are on the commercial side.
Show source
Varun Gupta: To answer this question, we are working for with the innovators from development in-phase molecules as well, and look at our mid as well, we have around 65% of the molecules which are in the in-phase stage of molecules and the rest 35% in the commercial side of it.
- The company said it was the global #1 player in Pyridine and Picolines and the only scaled non-Chinese player.
Show source
If I start with Specialty, I think Pyridine and Picolines are number 1.
- The company supplies ingredients to Lifesciences sectors including Pharma, Agrochemicals, Cosmetics and Semiconductors.
Show source
It is a combination of 2 words and we are truly and fundamentally an ingredients company which supply different kinds of ingredients into Lifesciences sectors such as Pharma, Agrochemicals, Cosmetics, now, even Semiconductors and many others, and we’ll talk about that more.
- The company is a domestic leader in choline, vitamin B4 and is expanding that portfolio with more specialty products.
Show source
We are domestic leader in choline, vitamin B4 and we are expanding that portfolio and adding more specialty products into it as well.
- The company has recently hired someone for Japan and has started its journey in Japan in the last few months.
Show source
So we have just started our journey in Japan in the last few months.
- Human nutrition products include choline chloride and choline bitartrate for pharmaceutical and nutritional products, and niacinamide for food and cosmetic applications.
Show source
While in human nutrition we have choline salts, which is like vitamin B4, in the form of choline chloride and choline bitartrate which goes in pharma as well as nutritional products.
- The company is planning to enter pre-mixes for nutraceuticals and nutritional powders and to identify more straight nutritional ingredients.
Show source
This apart, we are planning to foray into pre-mixes which goes into nutraceuticals Page 19 of 36 and nutritional powders.
- The company has launched choline chloride and choline bitartrate for human nutrition and pharmaceuticals and is ramping up those products.
Show source
That we are doubling down on human nutrition, so on human nutrition we are focusing on pre-mixes, we have already launched choline chloride and choline bitartrate, which goes into human nutrition and pharmaceuticals, we are ramping up those values.
- Speciality formulations for animal feed include vitamins, minerals pre-mixes, emulsifiers and herbal formulations, which have higher margins and more customer stickiness and traction in India and neighbouring markets.
Show source
We are also to go ahead with the capex, we are working on green filed GMP plant for choline chloride and choline bitartrate, and the third one is speciality formulations, now speciality formulations, these go into animal feed, these are like vitamins, minerals pre-mixes, emulsifiers, herbal formulations which go into feed which has more higher margin and more stickiness with the customer and which has more traction in India and the neighbouring markets.
- Semiconductor organic chemistries are not led by pyridine.
Show source
Semiconductors has some organic chemistries which we are experts in but none of them are led to pyridine.
- The company has no pyridine in its CDMO projects and says CDMO customers choose it for its chemistry capabilities and experience with process steps.
Show source
So that hopefully gives you a sense that what we are leveraging to push hard in our CDMO business is our chemistry capabilities, not necessarily pyridine as a product capability.
- The majority of Jubilant Ingrevia’s CDMO business is with innovators, not generics.
Show source
Ambrish Dixit: We can say that the majority of the CDMO business is with the innovators, we are not mixing it with the generics, it’s directly with innovators, we have been able to create a relationship and we are going deeper and we are Page 35 of 36 further expanding into the market and we have already shared that we have accelerated BD efforts and we have been recruiting more people in US, Europe and Japan.
- The company will continue to be a significant player in the Ethyl Acetate business. Replaced by a later filing.
Show source
Sir, we are still there, and we are still a significant player in the market and we will continue to be a significant player in this business.
Deals and partners
- The company announced some big contracts in the last 2 quarters and expects many more achievements and announcements in the next few quarters.
Show source
We have already announced some big contracts in the last 2 quarters and there’s many more achievements and announcements to come in the next few quarters.
- The company signed 2 new contracts with O2 renewable power that will take its power composition to almost 35% renewable.
Show source
This year, you saw in the video, we have signed 2 new Page 8 of 36 contracts with O2 renewable power just as an example, which will take our power composition to almost 35% renewable and we are not going to stop there, we will keep looking for more areas which can help us become more and more green in coming years.
- The company has provided several chemical intermediates to agrochemical innovators for almost 3 decades and is converting many of those relationships into CDMO-oriented relationships.
Show source
Now it’s time to capitalize on those strengths and covert many of those relationships into CDMO oriented relationships and that we announced 2 quarters back.
- The company has divided its CDMO business into Agro, Pharma and Semicon; it has signed a $300mn contract and has another contract with another innovator in CDMO Agro.
Show source
I think CDMO Agro, Deepak has already talked about, we have signed a $300mn contract, we have another contract with another innovator.
- CDMO business has 7 of its top 10 as big customers.
Show source
So, out of top 10, 7 are our big customers.
- The company identified almost 30-35 big customers for its key account management initiative, including some customers from acetyls; relationships from the acetyls portfolio have opened conversations about Jubilant Ingrevia's broader portfolio and newer opportunities.
Show source
We mapped out our big customers, identified almost 30-35 of them, some of them came from acetyls as well, as Himanshu explained, what acetyls portfolio does is that it gives us access to the big customers and on the back of those relationships, we have been able to open up conversations to talk about our broader portfolio and newer opportunities.
- The company is working with innovators and tier-1 CDMOs in Europe to increase sales directly to them.
Show source
On one side, we are trying to work with innovators to increase our sales, second, we are also working with their tier 1 CDMO in Europe where we can increase our sales directly to them.
- One of Jubilant Ingrevia's Agro CDMO relationships runs into hundreds of millions of dollars.
Show source
One of which runs into hundreds of millions of dollars.
- The company has created a large pipeline of customer molecules for CDMO projects, and some have converted; the company views the conversions as a multi-year journey and says announced big contracts give it confidence that further conversions will follow.
Show source
All of it we are looking as a multi-year journey and relationship, but a few big contracts that we have announced and what you saw coming as an upside blip in our revenue trajectory, gives us the confidence that the conversions will also follow.
Risks, rules and outside factors
Outside factors
- The company says its acetyl business, particularly anhydride, is driven by conditions in paracetamol and acetate markets; most customers in those markets are either not running their plants or operating at 40% to 50% utilization after six or eight tough quarters.
Show source
Both these markets have gone through tough times in the last, I would say, six or eight quarters, to an extent that most of our Page 14 of 36 customers are either not running their plants, or even if they are running, they are running them at 40% to 50% utilization only.
- China has overcapacity of up to 60%-70% in some products, so competition will remain.
Show source
There are products in China where the over capacity is upto 60%-70% and hence the competition will remain and of course it is a very uncertain world.
- The company purchased some power through exchange and signed short-term contracts this year, and signed a long-term contract that will benefit the company next year onwards.
Show source
Second, we feel we are sourcing our power differently, earlier we used to get all our power from grid except Gajraula and this year we have purchased some of the power through exchange and also signed short term contract, we have signed a long-term contract, which Deepak was saying, which will benefit down the line, next year onwards.
- The company believes Chinese tariffs would be higher than tariffs imposed on India, allowing it to sell more even if tariffs are imposed.
Show source
So, still that delta will allow us to sell more and also that will increase the cost of what we have seen over the time.
- The company believes tariff issues will not materially affect its sales.
Show source
So, we believe that this issue will not much impact on our sales.
Rules and policy
- US import duties are typically 6-7% where there is US manufacturing and zero where there is no US manufacturing; China has government duties of 10%+ in the example discussed.
Show source
So, that delta is large, you now, on forth of every, China has, the government has put some duties on them, 10%+, so if it is 0, then it is 10% and if it is 6.5% then it is 16.5%.
Everything else said on the call
What management stressed
- The company is doubling down on pharma, agro and nutrition, while expecting consumer to become relatively bigger through cosmetics and hair care.
Show source
So that's we are doubling down on.
- The company has accelerated business development efforts and has been recruiting more people in the US, Europe and Japan.
Show source
Ambrish Dixit: We can say that the majority of the CDMO business is with the innovators, we are not mixing it with the generics, it’s directly with innovators, we have been able to create a relationship and we are going deeper and we are Page 35 of 36 further expanding into the market and we have already shared that we have accelerated BD efforts and we have been recruiting more people in US, Europe and Japan.
- The company will not shy away from making investments as long as they meet the threshold criteria. Replaced by a later filing.
Show source
We will not shy away from making any investments, as long as it meets the threshold criteria.
Group structure
- The company has defined M&A areas to address portfolio gaps and accelerate its journey to Rs. 10-11,000-12,000cr, and has started listing potential targets and speaking with bankers; it will pursue a target that fits its thesis area.
Show source
So, organically, we already have a lot to do as you saw in the portfolio, so we of course want to, our first priority is to deliver on that, obviously as Partha is explaining that based on the thesis area that we have defined, we have already started to make a list of potential targets and we are also speaking to some bankers who are helping us, so as and when we find the right target in our thesis area, we will of course, go for it.
- The company is actively looking at several assets across business units for inorganic growth, which will play a part in its growth strategy.
Show source
So, it’s not a gambit, we are actively looking at quite a few assets in the space spread across the business units and we will talk about, you know, as and when it materializes, but it will play a part of our growth strategy.
People and governance
- Almost 50% of the leaders on Jubilant Ingrevia’s leadership team page took up their roles in the last 1.5-2 years.
Show source
As a leadership team, one of the things that you will see, almost 50% of the leaders from this page have taken up these roles in the last 1.5-2 years.
Show 5 more statements
People and governance
- Vishal has joined Jubilant Ingrevia to lead its human nutrition efforts.
Show source
Vishal has joined us and leading the human nutrition efforts for us.
Other
- The company has almost 150 employees dedicated to it at the Greater Noida R&D centre.
Show source
It houses almost 1,000 engineers across our group and almost 150 of them are dedicated to Ingrevia.
- The company has made almost 200 plus digital interventions across its plant, supply chain and front end, which have started to yield results.
Show source
Almost 200 plus interventions we have made across our plant, supply chain, even front end and have started to yield results.
- The company has 26+ Centres of Excellence working across different sites and functions and 60+ people in plants working on initiatives across sites.
Show source
We have 36+, sorry 26+ CoE who is working at different sites and functions and helping us to make sure that these interventions that we are developing are implemented.
- The company has another 300 digital interventions in the pipeline, to be developed and screened by the 26+ Centres of Excellence group of almost 80 people.
Show source
We have another 300 interventions in the pipeline with this group of 26+, almost 80 people, they are going to do a Page 25 of 36 funnel activity, identify the opportunities which we need to take to the next level and that is how the program will be driven throughout.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
This transcript does not separate questions and answers, so they are not listed here.
Questions about this call
- When was the Jubilant Ingrevia Q3 FY25 earnings call transcript filed?
- Jubilant Ingrevia filed the transcript with the exchange on 6 Mar 2025. This page is built from that transcript.
- What does this page list?
- 162 statements from the transcript across 14 topics, 102 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- No. This transcript does not separate the questions from the answers, so they are not listed. The statements by topic still cover what management said.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.